Freitag, 3. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Rekrutierend

NCT-Nummer:
NCT05713838

Studienbeginn:
August 2023

Letztes Update:
27.11.2023

Wirkstoff:
Durvalumab, FLOT, mFOLFOX-6

Indikation (Clinical Trials):
Adenocarcinoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborator:
-

Studienleiter

Salah-Eddin Al-Batran, Prof. Dr.
Study Chair
Institut für Klinische Krebsforschung IKF GmbH
Thorsten Götze, Prof. Dr.
Principal Investigator
Institute of Clinical Cancer Research, University Cancer Center (UCT) Frankfurt Krankenhaus Nordwest

Kontakt

Studienlocations
(3 von 16)

Klinikum St. Marien Kommunalunternehmen - Anstalt des öffentlichen Rechts der Stadt Amberg
Amberg
(Bayern)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Ludwig Fischer von Weikersthal, Dr.» Ansprechpartner anzeigen
Universitätsklinikum Brandenburg an der Havel Medizinische Hochschule Brandenburg
Brandenburg an der Havel
(Brandenburg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Mark Reinwald, PD Dr.» Ansprechpartner anzeigen
Institute of Clinical Cancer Research, University Cancer Center (UCT) Frankfurt Krankenhaus Nordwest
Frankfurt
(Hessen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Thorsten Götze, Prof. Dr.
Phone: 00496976014187
E-Mail: goetze.thorsten@khnw.de» Ansprechpartner anzeigen
Universitätsklinikum Halle (Saale) Universitätsklinik und Poliklinik für Innere Medizin I
Halle
(Sachsen-Anhalt)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Ulrich Ronellenfitsch, Prof. Dr.» Ansprechpartner anzeigen
Kreiskliniken Reutlingen GmbH Klinikum am Steinberg Reutlingen Ermstalklinik, Bad Urach
Reutlingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Stefan Kubicka, Prof. Dr.» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Detailed Description:

Patients with early stage, cT1 and cT2N0 esophageal adenocarcinoma with indication for

radical surgery (esophagectomy or transhiatal extended gastrectomy) will be enrolled in two

cohorts according to their PD-L1 CPS (cohort 1 CPS < 10, cohort 2 CPS ≥ 10). All patients

will receive core treatment consisting of immunotherapy with durvalumab in parallel to 2

cycles FLOT chemotherapy, followed by immunotherapy with durvalumab in parallel to 3 cycles

of modified FOLFOX plus concomitant radiation (50 Gy). Eight weeks after this, patients will

undergo tumor assessment consisting of esophagogastroduodenoscopy with extensive biopsies

(bite-on-bite biopsies and fine-needle aspiration), endoscopic ultrasonography with

measurement of maximum tumor thickness, and CT- or MRI-scans for tumor re-evaluation.

Surgical resection would be offered only to those patients in whom a locoregional persistence

is confirmed on tumor assessment, in the absence of any signs of distant dissemination.

Patients with complete remission will enter the maintenance phase receiving durvalumab

monotherapy for up to 12 cycles.

The primary objective of this trial is to investigate the treatment efficacy of the

combination of durvalumab and chemoradiation as organ preservative treatment option avoiding

mortality and surgical complications with rate of clinical and pathological complete response

(cCR/pCR) at time of endoscopic re-evaluation defined as primary efficacy endpoint.

The secondary objectives are the further assessment of the efficacy of the combination of

durvalumab and chemoradiation as organ preservative treatment option 1-/2- and 3-year cCR/pCR

rate, rate of salvage surgery, 90-day and 1-year mortality as secondary endpoints and to

assess the quality of life (QoL).

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Patient has given written informed consent.

2. Patient is, in the investigator's judgement, willing and able to comply with the study

protocol including the planned surgical treatment.

3. Patient is ≥ 18 years of age at time of signing the written informed consent.

4. Patient has been diagnosed with histologically confirmed esophageal adenocarcinoma

(including gastroesophageal junction (GEJ) (Siewert I- III)) with:

1. cT2 N0 M0 stage or T1 N0 M0 stage and a given indication for radical surgical

resection according to current S3-guidelines (this includes patients with a given

indication for radical surgery after endoscopic-resection of a cT1-2 N0 M0 tumor

[poor grading or L1/V1 invasion or basal R1 resection or deep submucosal

infiltration]).

2. tumor is considered medically and technically resectable.

5. Tumor is tested centrally (with validated assays, e.g., Dako PD-L1 IHC 22C3 or 28-8)

for PD-L1 according to combined positive score (CPS) and results must be available

prior study enrollment. In addition, a representative tumor specimen that is suitable

for central determination of PD-L1 TPS and MSI status is available. The analysis

requires paraffin embedded biopsy samples of the tumor to be provided to the Sponsor.

6. Patient has not received a prior cytotoxic or targeted therapy.

7. Patient has not had a prior complete esophagogastric tumor resection.

8. Patient has a ECOG ≤ 1.

9. Patient must have life expectancy of at least 12 weeks

10. Female patients of childbearing potential and male patients with female partners of

childbearing potential must agree to remain abstinent (refrain from heterosexual

intercourse) or use contraceptive methods that result in a failure rate of <1% per

year during the treatment period and for at least 6 months after the last study

treatment if it is in the core treatment phase or for at least 3 months after last

study treatment occurred in the maintenance phase. Male patients must refrain from

donating sperm during this same period. Male patients with a pregnant partner must

agree to remain abstinent or to use a condom for the duration of the pregnancy.

11. Patient has a body weight > 30 kg

12. Patient has adequate hematological, hepatic and renal function as indicated by the

following parameters:

1. Leukocytes ≥ 3,000/µL, platelets ≥ 100,000/µL without transfusion, absolute

neutrophil count (ANC) ≥ 1,500/µL without granulocyte colony-stimulating factor

support, hemoglobin ≥ 90 g/L (9 g/dL) - Patients may be transfused to meet this

criterion.

2. Bilirubin ≤ 1.5 x upper limit of normal (ULN), aspartate transaminase and alanine

transaminase ≤ 2.5 x ULN, alkaline phosphatase ≤ 2.5 x ULN

3. Serum creatinine ≤ 1.5 x ULN, or glomerular filtration rate > 45 mL/min

(calculated using the Cockcroft-Gault formula)

4. Serum albumin ≥ 25 g/L (2.5 g/dL)

5. For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN;

for patients receiving therapeutic anticoagulation: stable anticoagulant regimen

13. Patient has no human immunodeficiency virus (HIV) infection. NOTE: Patient with HIV

infection is eligible if he/she meets all the following criteria:

1. CD4 count is ≥350 cells/µL, viral load is undetectable, and not taking prohibited

cytochrome (CYP)-interacting medications

2. Probable long-term survival with HIV if cancer were not present

3. Stable on a highly active antiretroviral therapy (HAART) regimen for ≥4 weeks and

willing to adhere to their HAART regimen with minimal overlapping toxicity and

drug-drug interactions with the experimental agents in this study

4. HIV is not multi-drug resistant

5. Taking medication and/or receiving antiretroviral therapy that does not interact

or have overlapping toxicities with the study medication

Exclusion Criteria:

1. Patient has known hypersensitivity to any component of the durvalumab formulation as

well as a known history of severe allergic, anaphylactic, or other hypersensitivity

reactions to chimeric or humanized antibodies or fusion protein.

2. Patient has any known contraindication (including hypersensitivity) to docetaxel,

5-FU, leucovorin (calcium folinate), or oxaliplatin. In cases of pernicious anemia or

other anemias due to vitamin B 12 deficiency, folinic acid (Leucovorin) is

contraindicated and trial inclusion is not possible or only possible after

compensation the anaemic status.

3. Patient has a known dihydropyrimidine dehydrogenase (DPD) deficiency

4. Patient has an active or history of autoimmune disease including, but not limited to,

myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus,

rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome,

Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple

sclerosis, vasculitis, or glomerulonephritis.

NOTE: History of autoimmune-related hypothyroidism on a stable dose of thyroid

replacement hormone, or controlled Type 1 diabetes mellitus on a stable insulin

regimen may be eligible based on consultation with the sponsor's medical monitor.

Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with

dermatologic manifestations only (e.g., patients with psoriatic arthritis are

excluded) are eligible for the study provided all following conditions are met:

- Rash must cover < 10% of body surface area.

- Disease is well controlled at baseline and requires only low-potency topical

corticosteroids.

- No occurrence of acute exacerbations of the underlying condition requiring

psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents,

oral calcineurin inhibitors, or high potency or oral corticosteroids within the

previous 12 months.

5. Patient had a prior allogeneic bone marrow transplantation or prior solid organ

transplantation.

6. Patient has a history of idiopathic pulmonary fibrosis (including pneumonitis),

drug-induced pneumonitis, idiopathic pneumonitis, organizing pneumonia (i.e.,

bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active

pneumonitis on screening chest CT scan.

NOTE: History of radiation pneumonitis within the radiation field (fibrosis) is

permitted.

7. Patient has active hepatitis B (defined as having a positive hepatitis B surface

antigen [HBsAg] test prior to enrollment) or hepatitis C infection NOTE: Patients with

past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a

negative HBsAg test and a positive antibody to hepatitis B core antigen antibody test)

are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only

if polymerase chain reaction testing is negative for HCV ribonucleic acid (RNA).

8. Patient has active tuberculosis.

9. Patient has uncontrolled tumor-related pain (Patient requiring pain medication must be

on a stable regimen at study entry).

10. Patient received an administration of a live, attenuated vaccine within four weeks

prior to start of enrollment, or anticipation that such a live attenuated vaccine will

be required during the study or within 30 days after the last dose of durvalumab.

11. Patient had a prior treatment with CD137 agonists or immune checkpoint blockade

therapies, including anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibodies.

12. Patient had a treatment with systemic immunostimulatory agents (including but not

limited to interferons or interleukin-2) within four weeks or five half-lives of the

drug, whichever is longer, prior to study enrollment.

13. Patient had a treatment with systemic corticosteroids or other systemic

immunosuppressive medications within 2 weeks prior to initiation of study treatment.

The following are exceptions to this criterion:

1. Intranasal, inhaled, topical steroids or local steroid injections (e.g. intra

articular injection)

2. Systemic corticosteroids at physiologic dose not to exceed 10mg/day of prednisone

or its equivalent

3. Steroids as premedication for hypersensitivity reactions (e.g. CT premedication)

14. Patient has a significant cardiovascular disease, such as cardiac disease (New York

Heart Association Class II or greater), myocardial infarction or cerebrovascular

accident within 3 months prior to initiation of study treatment, unstable arrhythmias,

or unstable angina.

15. Patient has a clinically significant valvular defect.

16. Patient has a history of malignancy other than EGA within 5 years prior to screening,

with the exception of malignancies with a negligible risk of metastasis or death (e.g.

5-year OS rate >90%), such as adequately treated carcinoma in situ of the cervix,

non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or

Stage I uterine cancer.

17. Patient has peripheral polyneuropathy ≥ NCI CTCAE grade 2.

18. Patient has uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L,

calcium > 12 mg/dL or corrected serum calcium > ULN).

19. Patient has a serious infection requiring oral or IV antibiotics within 14 days prior

to study enrollment.

20. Patient has chronic inflammatory bowel disease.

21. Patient has clinically significant active gastrointestinal bleeding.

22. Patient underwent major surgical procedure other than for diagnosis within 4 weeks

prior to initiation of study treatment.

23. Patient has evidence of any other disease, neurologic or metabolic dysfunction,

physical examination finding or laboratory finding giving reasonable suspicion of a

disease or condition that contraindicates the use of any of the study medications,

puts the patient at higher risk for treatment-related complications or may affect the

interpretation of study results.

24. Patients participated in another interventional clinical study ≤ 30 days prior to

study enrollment or participation in such a study at the same time as this study.

25. Patient has taken an investigational drug within 28 days prior to initiation of study

drug.

26. Female patient is pregnant or breast feeding or planning to become pregnant within and

6 months after the end of treatment. Female patients of childbearing potential must

have a negative serum pregnancy test result within 7 days prior to initiation of study

treatment.

Studien-Rationale

Primary outcome:

1. Rate of clinical and pathological complete response (cCR/pCR) (Time Frame - 8 weeks after completion of core treatment):
Rate of clinical and pathological complete response rate at time of endoscopic re-evaluation (at the end of the core study treatment) according to Becker criteria and investigator-based RECIST v1.1 assessment as well as endoscopic response criteria similar to the Japanese Gastric Cancer Association Guideline



Secondary outcome:

1. Rate of cCR/pCR (long term follow up) (Time Frame - 1, 2 and 3 years after start of treatment):
Rate of cCR/pCR at 1, 2 and 3 years after start of treatment (long term follow up)

2. Subgroup analysis of cCR/pCR (Time Frame - 8 weeks after completion of core treatment and after 1 year):
Subgroup analysis of cCR/pCR rate at time of endoscopic re-evaluation and after 1 year according to following characteristics: MSI high, PD-L1 CPS>1 and PD-L1 CPS>5 and especially acc. to CPS ≥10 or <10

3. Rate of salvage surgery (Time Frame - up to 48 months):
Rate of salvage surgery

4. Mortality (Time Frame - 90 days, 12 months after start of treatment):
90-day as well as 1-year mortality after start of treatment in non-surgery population and population with salvage surgery

5. Determination of the sites of tumor relapse (Time Frame - up to 48 months):
Determination of the sites of tumor relapse

6. Safety Endpoints (Time Frame - up to 20 months):
Incidence of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) as assessed during treatment and until 90 days after the last dose of study drug Severity of adverse events by CTCAE v5.0 grade Relationship of adverse events to the durvalumab, chemotherapy and/or radiation Frequency of clinically significant abnormal laboratory parameters to CTCAE (Common Terminology Criteria for Adverse Events)

Geprüfte Regime

  • Durvalumab (IMFINZI):
    1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)
  • FLOT:
    50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles
  • mFOLFOX-6:
    85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
  • Radiotherapy:
    5 weeks with 5 days a week radiotherapy (25 daily fractions with 2.0 Gy = ∑50Gy)

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.